Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17892945 | 0.82 | TSHR (0.44) | RAB9ANPC1TSHROPRM1OPRL1 | |
| SCHEMBL17892947 | 0.82 | MAPK1 (0.49) | RAB9ANPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL14711534 | 0.77 | HPGD (0.47) | RAB9ANPC1HPGDMAPTKDM4E | |
| SCHEMBL5520135 | 0.75 | ALDH1A1 (0.36) | RAB9ANPC1TSHROPRM1OPRL1 | |
| SCHEMBL15897081 | 0.75 | RAB9A (0.42) | RAB9ANPC1TSHRMAPTKDM4E | |
| SCHEMBL20919672 | 0.72 | RAB9A (0.40) | RAB9ANPC1TSHRMAPTKDM4E | |
| SCHEMBL15241016 | 0.72 | OPRM1 (0.35) | RAB9ANPC1HPGDTSHROPRM1 | |
| SCHEMBL5522061 | 0.71 | GBA1 (0.39) | RAB9ANPC1OPRM1OPRL1KDM4E | |
| SCHEMBL1093908 | 0.70 | ATM (0.50) | RAB9ANPC1TSHRMAPTKDM4E | |
| SCHEMBL30805980 | 0.70 | ALDH1A1 (0.43) | RAB9AHPGDOPRM1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-3240542-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-10130630-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170340631-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3240542-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240543-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109216-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109215-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130630-B2 | BTK inhibitors | BTK, SYK, LYN | RAB9A 2033/4885NPC1 3116/4885HPGD 4206/4885 |
| US-20180118766-A1 | BTK INHIBITORS | BTK, SYK, LYN | RAB9A 2196/4885NPC1 2994/4885HPGD 3980/4885 |
| US-20170340631-A1 | BTK INHIBITORS | BTK, SYK, LYN | RAB9A 2033/4885NPC1 3116/4885HPGD 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.